Abstract
John Murphy, M.D., M.P.H., D.P.H., President The Covid-19 Long-haul Foundation
Long COVID, also termed post-acute sequelae of SARS-CoV-2 infection (PASC), has emerged as a chronic multisystem disorder affecting millions worldwide. Although respiratory, neurologic, and cardiovascular manifestations have dominated public discussion, dermatologic sequelae are increasingly recognized as a major component of persistent post-viral disease. Long-haul cutaneous pathology includes chronic inflammatory eruptions, dysautonomic vasculopathy, endothelial injury, mast-cell dysregulation, persistent urticaria, alopecia, microvascular ischemia, connective tissue abnormalities, nail pathology, and impaired barrier function. Emerging evidence suggests that persistent viral reservoirs, immune dysregulation, endothelial dysfunction, coagulation abnormalities, mitochondrial injury, autoimmunity, and mast-cell activation contribute to ongoing dermatologic disease in long COVID patients.
This article reviews the current scientific understanding of long COVID skin disease, examining etiology, immunopathogenesis, histopathology, clinical manifestations, disease progression, diagnostic evaluation, and evidence-based therapeutic interventions. Particular emphasis is placed on endothelial inflammation, persistent cytokine signaling, dysregulated innate immunity, and chronic microvascular injury as unifying mechanisms underlying many post-COVID dermatologic syndromes. Contemporary approaches to skin care, systemic therapy, barrier restoration, photoprotection, anti-inflammatory interventions, and emerging therapeutics are evaluated within the broader context of chronic post-viral inflammatory disease.
Introduction
The dermatologic manifestations of SARS-CoV-2 infection were initially regarded as secondary or incidental findings during the acute phase of the COVID-19 pandemic. Early reports focused primarily on transient viral exanthems, urticaria, vesicular eruptions, chilblain-like lesions, and livedoid vascular phenomena. Over time, however, it became apparent that a substantial subset of patients developed persistent or delayed cutaneous abnormalities extending months or years beyond the acute infection.
Long COVID is now understood as a heterogeneous, multisystemic syndrome characterized by persistent immune activation, endothelial injury, dysautonomia, coagulation abnormalities, mitochondrial dysfunction, and chronic inflammatory signaling. Dermatologic involvement represents one of the most visible manifestations of these systemic abnormalities. Unlike transient viral rashes associated with many infectious diseases, long COVID skin pathology frequently demonstrates chronicity, relapse-remission patterns, autoimmune overlap, and evidence of persistent vascular inflammation.
The skin serves as both an immune organ and a vascular interface. Consequently, persistent systemic inflammation and endothelial dysfunction are readily reflected in cutaneous tissues. The skin contains abundant mast cells, macrophages, dendritic cells, endothelial cells, and resident T lymphocytes, all of which may participate in chronic post-COVID immune dysregulation. These mechanisms help explain why patients with long COVID frequently develop persistent erythema, urticarial syndromes, dysautonomic flushing, acrocyanosis, vasculitic lesions, delayed wound healing, and accelerated barrier dysfunction.
The dermatologic burden of long COVID is clinically significant. Persistent skin disease contributes to pain, pruritus, sleep disruption, psychosocial distress, body-image impairment, occupational disability, and diminished quality of life. Hair loss alone, particularly telogen effluvium, has become one of the most frequently reported long COVID manifestations.
Despite increasing recognition, long COVID dermatology remains poorly standardized diagnostically and therapeutically. The literature is complicated by inconsistent terminology, heterogeneity of patient populations, varying follow-up durations, and evolving definitions of PASC. Nonetheless, a coherent pathophysiologic framework is emerging.
Epidemiology of Long COVID Skin Disease
Precise epidemiologic estimates remain difficult because dermatologic manifestations are often underreported, misclassified, or overshadowed by neurologic and cardiopulmonary symptoms. Nevertheless, observational cohorts suggest that cutaneous manifestations occur in a meaningful proportion of long COVID patients.
Registry analyses and systematic reviews have identified a wide spectrum of persistent dermatologic findings including:
- Chronic urticaria
- Pernio-like lesions (“COVID toes”)
- Livedo reticularis
- Papulosquamous eruptions
- Persistent maculopapular eruptions
- Rosacea-like inflammation
- Dysautonomic flushing
- Telogen effluvium
- Nail dystrophy
- Small-vessel vasculitis
- Hyperpigmentation
- Delayed wound healing
- Persistent pruritus
Systematic reviews have found alopecia to be among the most common persistent cutaneous findings after SARS-CoV-2 infection.
Women appear disproportionately represented among reported long COVID dermatologic cohorts, paralleling broader long COVID epidemiology. Several mechanisms have been proposed, including sex-based immune differences, autoimmune susceptibility, hormonal influences on mast-cell function, and differential inflammatory responses.
Importantly, dermatologic manifestations may occur even after mild acute infections. Long COVID skin disease is not restricted to previously hospitalized patients.
Etiology and Pathogenesis
Viral Persistence
One leading hypothesis proposes that persistent SARS-CoV-2 reservoirs contribute to chronic immune activation. Viral RNA and protein fragments have been detected in multiple tissues months after acute infection, suggesting incomplete viral clearance in certain individuals. Persistent antigenic stimulation may sustain chronic inflammatory signaling within the skin and vascular system.
Cutaneous tissues are immunologically active and richly vascularized, making them vulnerable to ongoing immune-mediated injury. Viral persistence may trigger continuous activation of macrophages, mast cells, endothelial cells, and T lymphocytes, producing chronic inflammatory skin disease.
Persistent viral antigen may also contribute to:
- Chronic interferon activation
- Endothelial inflammation
- Microvascular thrombosis
- Autoantibody generation
- Mast-cell hyperreactivity
- Fibrotic remodeling
These processes potentially explain recurrent or relapsing dermatologic symptoms observed in many long COVID patients.
Immune Dysregulation
Long COVID is increasingly viewed as a disorder of persistent immune dysregulation. Studies demonstrate abnormalities involving:
- T-cell exhaustion
- Cytokine imbalance
- Persistent interferon signaling
- Autoantibody production
- Dysregulated innate immunity
- Chronic inflammatory activation
The skin is especially vulnerable to immune imbalance because of its role as a frontline immunologic organ. Chronic cytokine activation may impair epidermal barrier integrity, alter sebaceous function, promote vascular inflammation, and sustain pruritic or inflammatory eruptions.
Elevated inflammatory mediators implicated in long COVID include:
- Interleukin-6 (IL-6)
- Tumor necrosis factor alpha (TNF-α)
- Interferon gamma
- Interleukin-1β
- Histamine
- Transforming growth factor beta
These mediators contribute to endothelial dysfunction, collagen remodeling, vascular instability, mast-cell activation, and epidermal injury.
Endothelial Dysfunction and Microvascular Injury
One of the most compelling mechanisms underlying long COVID skin disease involves endothelial dysfunction. SARS-CoV-2 infects endothelial tissues through ACE2-mediated pathways and may produce widespread vascular inflammation.
Endothelial injury contributes to:
- Capillary leakage
- Microthrombi formation
- Tissue hypoxia
- Impaired wound healing
- Dysautonomic vasoreactivity
- Livedoid lesions
- Acrocyanosis
- Chronic erythema
The skin’s dense microvascular network renders it particularly sensitive to persistent endothelial inflammation. Histopathologic studies have demonstrated complement activation, fibrin deposition, endothelial swelling, and perivascular lymphocytic infiltrates in COVID-related cutaneous lesions.
Microvascular compromise may also impair nutrient delivery to hair follicles, contributing to chronic alopecia.
Mast Cell Activation
Mast-cell activation has emerged as a major area of investigation in long COVID research. Mast cells are abundant in the skin and regulate vascular permeability, histamine release, pruritus, neuroimmune communication, and inflammatory signaling.
Several studies and clinical observations suggest overlap between long COVID and mast-cell activation syndrome (MCAS).
Mast-cell dysregulation may contribute to:
- Flushing
- Urticaria
- Dermatographism
- Pruritus
- Facial erythema
- Heat intolerance
- Dysautonomic skin symptoms
- Edema
- Rosacea-like inflammation
Persistent mast-cell activation may also amplify neurogenic inflammation and contribute to chronic hypersensitivity syndromes.
Autoimmunity
Autoimmune mechanisms are increasingly implicated in long COVID. Molecular mimicry between SARS-CoV-2 proteins and host tissues may trigger autoantibody formation and immune-mediated tissue injury.
Autoimmune overlap syndromes reported after COVID include:
- Lupus-like syndromes
- Vasculitis
- Psoriasis exacerbation
- Connective tissue abnormalities
- Autoimmune alopecia
- Scleroderma-like changes
Autoimmune skin pathology may emerge months after infection and may persist chronically.
Histopathology
Histopathologic findings in long COVID skin disease vary according to lesion type but commonly include:
- Perivascular lymphocytic infiltrates
- Endothelial swelling
- Microvascular thrombosis
- Interface dermatitis
- Mast-cell infiltration
- Epidermal spongiosis
- Complement deposition
- Fibrin accumulation
- Dermal edema
Some biopsies reveal evidence of persistent endothelial activation and chronic immune-cell recruitment.
Pernio-like lesions often demonstrate lymphocytic vasculitis and interferon-mediated inflammation, whereas livedoid lesions may demonstrate thrombotic vasculopathy and endothelial injury.
Hair-loss syndromes frequently demonstrate premature follicular transition into telogen phase, perifollicular inflammation, and microvascular compromise.
Clinical Manifestations
Telogen Effluvium and Hair Loss
Hair loss is among the most common long COVID dermatologic manifestations.
Most cases represent telogen effluvium, a condition in which systemic stress shifts hair follicles prematurely into resting phase. However, some patients exhibit prolonged or relapsing alopecia suggestive of chronic inflammatory dysregulation rather than transient physiologic stress alone.
Contributing mechanisms may include:
- Cytokine-mediated follicular injury
- Microvascular ischemia
- Nutritional depletion
- Chronic inflammation
- Endocrine dysregulation
- Autoimmune activation
Hair loss may persist for many months and significantly impair psychological well-being.
Chronic Urticaria
Persistent urticaria has become increasingly recognized after SARS-CoV-2 infection. Chronic histamine-mediated wheals may be accompanied by dermatographism, angioedema, and severe pruritus.
Potential mechanisms include:
- Mast-cell hyperactivation
- Autoantibodies
- Persistent cytokine signaling
- Dysregulated immune tolerance
Patients often report exacerbation with heat, stress, exercise, or certain foods.
Pernio-Like Lesions (“COVID Toes”)
Pernio-like lesions represent one of the most characteristic COVID-associated skin findings. In some patients these lesions persist for months.
Clinical features include:
- Violaceous discoloration
- Painful nodules
- Swelling
- Burning sensation
- Cold sensitivity
Histology often demonstrates interferon-mediated vascular inflammation and endothelial injury.
Livedo Reticularis and Vasculopathy
Reticular vascular patterns may reflect ongoing microvascular dysfunction and coagulation abnormalities.
These lesions may signal:
- Endothelial inflammation
- Hypercoagulability
- Capillary obstruction
- Persistent thromboinflammatory disease
Persistent Pruritus
Chronic itching is a frequent but underrecognized long COVID symptom. Mechanisms may include:
- Mast-cell activation
- Neurogenic inflammation
- Small-fiber neuropathy
- Barrier dysfunction
- Cytokine signaling abnormalities
Persistent pruritus can substantially impair sleep and mental health.
Rosacea-Like and Seborrheic Syndromes
Many patients develop persistent facial erythema, flushing, seborrheic dermatitis, or rosacea-like inflammation following COVID.
Potential contributors include:
- Neurovascular dysregulation
- Dysautonomia
- Mast-cell activation
- Altered microbiome function
- Barrier disruption
Nail Changes
Reported nail abnormalities include:
- Beau lines
- Onychomadesis
- Brittle nails
- Chromonychia
These findings likely reflect systemic inflammatory stress and microvascular compromise affecting nail-matrix function.
Disease Progression
Long COVID dermatologic disease often follows a fluctuating course characterized by relapse-remission cycles. Symptoms may worsen after:
- Physical exertion
- Heat exposure
- Emotional stress
- Secondary infections
- Hormonal changes
This pattern resembles other chronic inflammatory and dysautonomic disorders.
Some patients improve gradually over 12–24 months, whereas others develop persistent chronic disease.
Persistent endothelial injury and immune dysregulation may drive ongoing tissue remodeling and chronic inflammatory susceptibility.
Diagnostic Evaluation
Comprehensive evaluation should include:
- Detailed clinical history
- Timing relative to SARS-CoV-2 infection
- Review of systemic symptoms
- Medication history
- Autoimmune screening
- Nutritional assessment
- Dermatologic examination
Potential laboratory studies include:
- CBC
- Ferritin
- ANA
- ESR
- CRP
- Thyroid studies
- Vitamin D
- Zinc
- Iron studies
- Mast-cell mediators in selected cases
Skin biopsy may help distinguish inflammatory, autoimmune, vasculitic, or thrombotic pathology.
Therapeutic Strategies
Barrier Restoration
Skin-barrier dysfunction appears common in long COVID inflammatory dermatoses.
Core interventions include:
- Gentle non-soap cleansers
- Ceramide-based moisturizers
- Occlusive repair therapies
- Fragrance avoidance
- Humidification
Barrier restoration may reduce neuroimmune activation and pruritus.
Photoprotection
Ultraviolet exposure may exacerbate inflammatory skin disease and oxidative stress.
Recommended measures include:
- Broad-spectrum mineral sunscreens
- UV-protective clothing
- Avoidance of excessive sun exposure
- Antioxidant support
Anti-Inflammatory Topicals
Topical corticosteroids remain useful for inflammatory eruptions but should be employed judiciously.
Steroid-sparing therapies include:
- Topical calcineurin inhibitors
- Azelaic acid
- Metronidazole
- Sulfur preparations
- Colloidal oatmeal formulations
These therapies may benefit rosacea-like and mast-cell-mediated syndromes.
Antihistamines and Mast-Cell Stabilization
Because mast-cell activation may contribute substantially to symptoms, antihistamine therapy is frequently beneficial.
Agents used clinically include:
- Cetirizine
- Fexofenadine
- Loratadine
- Famotidine
Some clinicians employ mast-cell stabilizers such as cromolyn sodium in selected patients.
Hair-Loss Therapies
Management of telogen effluvium may include:
- Nutritional optimization
- Iron correction
- Stress reduction
- Minoxidil
- Anti-inflammatory scalp therapies
Hair regrowth often occurs gradually but may require prolonged treatment.
Nutritional Interventions
Nutritional deficiencies may worsen skin-barrier dysfunction and hair loss.
Important nutrients include:
- Zinc
- Iron
- Vitamin D
- Essential fatty acids
- Protein
Anti-inflammatory dietary approaches may also reduce systemic inflammatory burden.
Microvascular Support
Given the role of endothelial dysfunction, strategies targeting vascular health may prove beneficial.
Potential interventions under investigation include:
- Omega-3 fatty acids
- Nitric oxide support
- Antioxidants
- Compression therapies
- Exercise pacing
However, evidence remains limited.
Psychological Support
Chronic visible skin disease frequently produces anxiety, depression, social withdrawal, and body-image disturbance.
Integrated psychological support should be considered part of comprehensive care.
Emerging Therapeutics
Research into long COVID therapeutics is evolving rapidly.
Areas of investigation include:
- Antiviral therapies
- Immunomodulators
- Mast-cell-targeted therapies
- Anticoagulant approaches
- Mitochondrial support agents
- Microbiome-directed therapies
Biologic therapies targeting IL-6, TNF-α, and other inflammatory mediators may eventually prove useful in selected severe inflammatory dermatologic syndromes.
Low-dose naltrexone has also attracted attention because of potential anti-inflammatory and microglial-modulating effects, although controlled evidence remains limited.
Skin Care Recommendations for Long COVID Patients
Practical dermatologic care principles include:
- Avoid aggressive exfoliation.
- Use fragrance-free barrier-repair moisturizers.
- Maintain consistent photoprotection.
- Avoid overheating and excessive hot water exposure.
- Employ gentle scalp care.
- Identify mast-cell triggers when present.
- Maintain adequate hydration.
- Optimize sleep quality.
- Pace physical exertion.
- Seek early dermatologic evaluation for progressive lesions.
Future Directions
Long COVID dermatology remains an evolving field. Major unanswered questions include:
- The degree of viral persistence in cutaneous tissues
- The role of latent viral reactivation
- Mechanisms of endothelial injury
- Long-term autoimmune risk
- Optimal immunomodulatory therapies
- Biomarkers predicting chronicity
Large prospective cohort studies and standardized diagnostic criteria remain urgently needed.
Conclusion
Long COVID skin disease represents a complex intersection of persistent inflammation, endothelial dysfunction, mast-cell activation, immune dysregulation, autoimmunity, and microvascular injury. Dermatologic manifestations are neither trivial nor merely cosmetic; they frequently reflect broader systemic pathology associated with chronic post-viral disease.
Current evidence supports a multifactorial model involving persistent immune activation, dysregulated vascular biology, mitochondrial dysfunction, and aberrant inflammatory signaling. Cutaneous manifestations may serve as visible biomarkers of systemic long COVID pathophysiology.
Therapeutic management remains largely symptomatic and supportive, emphasizing barrier restoration, anti-inflammatory therapy, mast-cell stabilization, vascular support, nutritional optimization, and individualized dermatologic care. Future advances will depend upon improved mechanistic understanding and carefully designed longitudinal research.
As recognition of long COVID expands, dermatologists and clinicians must increasingly view persistent cutaneous disease not as isolated skin pathology, but as part of a broader chronic inflammatory syndrome requiring multidisciplinary evaluation and treatment.
References
- Dermatology Mirza FN, Malik AA, Omer SB, Sethi A. Dermatologic manifestations of COVID-19: a comprehensive systematic review. Int J Dermatol. 2021.
- McMahon DE et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. Lancet Infect Dis. 2021.
- Grover A et al. Long-term cutaneous manifestations in COVID-19 patients: A systematic review. J Am Acad Dermatol. 2022.
- Davis HE et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023.
- Altmann DM et al. The immunology of long COVID. Nat Rev Immunol. 2023.
- Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022.
- Crook H et al. Long COVID—mechanisms, risk factors, and management. BMJ. 2021.
- Nalbandian A et al. Post-acute COVID-19 syndrome. Nat Med. 2021.
- Yong SJ. Persistent brainstem dysfunction in long-COVID. ACS Chem Neurosci. 2021.
- Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19. Front Microbiol. 2021.
- Su Y et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022.
- Schwartzberg LN et al. A systematic review of dermatologic manifestations among adult patients with COVID-19 diagnosis. Skin Health Dis. 2021.
- Yong SJ. Long COVID and endothelial dysfunction. Med Hypotheses. 2021.
- Venter C et al. Coagulation abnormalities and microclots in long COVID. Cardiovasc Diabetol. 2022.
- Pretorius E et al. Persistent clotting protein pathology in long COVID. Cardiovasc Diabetol. 2021.
- Weinstock LB et al. Mast cell activation symptoms are prevalent in Long-COVID. Int J Infect Dis. 2021.
- Freeman EE et al. COVID-19 and cutaneous manifestations. J Am Acad Dermatol. 2020.
- Gisondi P et al. Cutaneous manifestations of SARS-CoV-2 infection. Clin Dermatol. 2021.
- Kaya G et al. Histopathology of COVID-19 skin lesions. J Eur Acad Dermatol Venereol. 2020.
- Marzano AV et al. Cutaneous manifestations in patients with COVID-19. J Am Acad Dermatol. 2020.
- Magro C et al. Complement associated microvascular injury and thrombosis in COVID-19. Transl Res. 2020.
- Huertas A et al. Endothelial cell dysfunction in COVID-19. Eur Respir J. 2020.
- Singh KK et al. Mitochondrial dysfunction in long COVID. Mitochondrion. 2022.
- Peluso MJ et al. Persistent immune activation in post-acute sequelae of SARS-CoV-2 infection. J Clin Invest. 2021.
- Fernández-de-Las-Peñas C et al. Defining long COVID. J Infect. 2021.
- Dermatological complications due to post-COVID-19 syndrome: A systematic review. 2024.
- Pathophysiology and mechanism of long COVID: a comprehensive review. 2022.